Agenerase resistance
Executive Summary
Fewer isolates cultured from heavily pre-treated HIV patients were found to be resistant to Agenerase, according to in vitro data presented at ICAAC. Twenty-four percent of isolates demonstrated eight-fold resistance to amprenavir vs. 43% resistance to indinavir, 63% resistance to Abbott's Norvir (ritonavir), 61% resistance to Roche's Viracept (nelfinavir) and 53% resistance to Roche's Invirase/Fortovase (saquinavir)